Drug Type Small molecule drug |
Synonyms IDP 601, IDP-601 |
Target |
Mechanism HIF-1α inhibitors(Hypoxia-inducible factor 1 alpha inhibitors), HIF-2α inhibitors(Endothelial PAS domain-containing protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization IDP Discovery Pharma SLStartup |
Active Organization IDP Discovery Pharma SLStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Renal Cell Carcinoma | Preclinical | ES | IDP Discovery Pharma SLStartup | 17 Jun 2024 |
Hepatocellular Carcinoma | Preclinical | ES | IDP Discovery Pharma SLStartup | 30 Aug 2023 |
Respiratory Diseases | Preclinical | ES | IDP Discovery Pharma SLStartup | 30 Aug 2023 |
Triple Negative Breast Cancer | Preclinical | ES | IDP Discovery Pharma SLStartup | 30 Aug 2023 |